Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

African Countries Urged To Back New Medicines Agency

Obstacles Include Lack Of Political Will

Executive Summary

COVID-19 has highlighted the need for greater harmonization of medicines regulation to tackle health issues and emergencies more effectively in Africa. With that in mind, countries are being encouraged to speed up their ratification of a treaty setting up a new pan-African body tasked with coordinating national regulatory efforts, improving access to quality medicines and supporting the local pharmaceutical industry.

You may also be interested in...



African Medicines Agency To Be Established In 2022

Enough African countries have now ratified the AMA treaty to allow it to come into force next month.

New Alliance Urges Countries To Ratify Treaty On African Medicines Agency

Stakeholders are making a concerted effort to get the new agency off the ground, saying it will not only reduce drug approval times but help to drive industrial and economic growth in Africa. The European Medicines Agency is offering to share its experience in regulatory collaboration and network building.

Regulatory Harmonization Makes Big Strides In Africa

Last month a drug for the prevention of uterine haemorrhage became the first product to be approved under a novel scheme designed to speed up access to medicines in low and middle-income countries, particularly those in sub-Saharan Africa. 

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS143479

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel